BORJE S ANDERSSON to DNA
This is a "connection" page, showing publications BORJE S ANDERSSON has written about DNA.
Connection Strength
0.289
-
HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs. Oncotarget. 2022 10 14; 13:1122-1135.
Score: 0.117
-
In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia. Cancer Res. 1987 Feb 15; 47(4):1040-4.
Score: 0.040
-
Leukemic cell versus plasma levels of daunorubicin and daunorubicinol after infusion of daunorubicin as free drug or the DNA complex. Cancer Chemother Pharmacol. 1980; 4(3):205-7.
Score: 0.024
-
Uptake and distribution of daunorubicin and daunorubicin-DNA complex in mice as studied by whole-body autoradiography and liquid chromatography. Cancer Chemother Pharmacol. 1979; 2(3):159-67.
Score: 0.023
-
Complete sequence of a 38.4-kb human cosmid insert containing the polymorphic marker DXS455 from Xq28. DNA Seq. 1995; 5(4):219-23.
Score: 0.017
-
Mutations causing defective splicing in the human hprt gene. Environ Mol Mutagen. 1992; 20(2):89-95.
Score: 0.014
-
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells. Biochem Pharmacol. 1987 Dec 01; 36(23):4067-77.
Score: 0.010
-
The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem Biophys Res Commun. 1987 Apr 29; 144(2):787-93.
Score: 0.010
-
Significance of cellular pharmacokinetics for the cytotoxic effects of daunorubicin. Cancer Res. 1982 Jan; 42(1):178-83.
Score: 0.007
-
Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients. Cancer Chemother Pharmacol. 1981; 5(4):261-6.
Score: 0.006
-
Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex. Cancer Chemother Pharmacol. 1979; 2(1):15-7.
Score: 0.006
-
Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex. Cancer Chemother Pharmacol. 1979; 2(1):19-24.
Score: 0.006
-
Screening for mutations in human HPRT cDNA using the polymerase chain reaction (PCR) in combination with constant denaturant gel electrophoresis (CDGE). Mutat Res. 1992 Sep; 269(1):41-53.
Score: 0.004
-
Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia. Oncogene. 1989 Jan; 4(1):93-8.
Score: 0.003
-
The c-abl, bcr and C lambda genes are amplified in a cell line but not in the uncultured cells from a patient with chronic myelogenous leukemia. Leuk Res. 1986; 10(12):1401-9.
Score: 0.002